based on three times Taiwans GDP, the probabilities of using a GLP-1RA versus insulin therapy being cost-effective for preventing one case of all-cause mortality and hospitalized hypoglycemia were 60% (100%) and 80% (100%), respectively, from the payer perspective (healthcare sector perspective)
PMID: 15375005
Right now, there isnt data to show that BPC-157 is harmful to the liverbut we dont have enough data to suggest its safe, either
These systems are tightly interconnected, and when they are disrupted, the bodys capacity to resolve pain is significantly reduced
That part doesnt change based on which peptide you choose.If you want that kind of structured approach, physician-led evaluation, baseline and ongoing IGF-1 monitoring, honest sourcing, and a protocol matched to your goal rather than a default, thats the model TRTMD is built around